Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Mydecine Innovations Group Inc
(OP:
MYCOF
)
0.0074
-0.0032 (-30.19%)
Streaming Delayed Price
Updated: 12:54 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Mydecine Innovations Group Inc
< Previous
1
2
3
Next >
EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
July 31, 2024
Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy.
Via
Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
February 15, 2024
Via
Benzinga
Mydecine Innovations Group gearing up for human trials after completing Aquis listing
October 18, 2023
--News Direct--
Via
News Direct
Psyched: FDA Warning, DEA's Telehealth Extension, CA Gov's Veto, Congress On Kratom, M&As & More
October 16, 2023
Cybin And Small Pharma Shareholders Green Light Acquisition Resolution
Via
Benzinga
Exposures
Product Safety
Mydecine Reports Financial Results For 2021
April 01, 2022
Via
Benzinga
Psychedelic-Based Drugs Biotech Company Begins Trading On UK's AQSE Growth Market
October 12, 2023
Novel psychedelic-based drugs biotech Mydecine Innovations Group, Inc. (NEO:MYCO) (AQSE: MYIG) (OTC: MYCOF) (FSE: 0NFA) completed its admission to Access segment of the UK’s stock market, AQSE Growth...
Via
Benzinga
Psyched: Fed Study On Psychedelics, Janet Yellen's Magic Mushrooms, Financing Deals & Quarterly Reports
August 21, 2023
Cannabis, Psychedelics Use And Binge Drinking At All-Time High Among Adults, Teens Remain Stable, Fed Study Finds
Via
Benzinga
Topics
Cannabis
Economy
Exposures
Cannabis
Interest Rates
Mydecine Releases Q2 2023: Developer Of Smoke Cessation Psilocybin Prodrugs & MDMA Analogs
August 15, 2023
Novel psychedelic-based drugs biotech Mydecine Innovations Group (OTC: MYCOF) shared its financial results for the six months ended June 30, 2023. Second quarter of FY2023 looks like this: Cash...
Via
Benzinga
Jamaica Launches Organic Psilocybin Gummies & New Psychedelic Retreat: Rose Hill's New Offer
August 01, 2023
Rose Hill, a Jamaica-based cultivator, supplier and exporter of premium psilocybin products and biomass to research partners and brands is now offering its first wellness retreat program under the name...
Via
Benzinga
Mydecine's Prospectus Supplement Closing Under Share Subscription And Management Update
May 30, 2023
Colorado-based next-generation psychedelics biotech Mydecine Innovations Group Inc. (OTC: MYCOF) announced that, in connection with its common share subscription agreement with a third-party investor...
Via
Benzinga
Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More
May 23, 2023
Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application...
Via
Benzinga
Mydecine's Q1 2023 Reports Shows Decline In Assets And R&D, Increase In Net Loss And Accumulated Deficit
May 17, 2023
Psychedelics biotech Mydecine Innovations Group (OTC: MYCOF) shared its condensed interim (unaudited) financial results for three months ended March 31, 2023. First quarter numbers:
Via
Benzinga
Psyched: Oregon And Colorado Regulations, MindMed CEO Discusses LSD Therapy, Mia Khalifa Enters Market & More
May 01, 2023
Oregon Pioneers Legal Psilocybin Therapy, But This Type Of License Has Yet To Be Issued
Via
Benzinga
New Set Of MDMA Analogs To Hit The Clinic: These Are The Latest Positive Findings
April 25, 2023
Psychedelics biotech Mydecine Innovations Group (OTC: MYCOF) is advancing the development of its novel compounds family of next-gen MDMA analogs. So far, Mydecine's compounds show promising...
Via
Benzinga
Mydecine: 2022 Financials & Business Update By Next-Gen Psychedelics Producer, Smoke Cessation Trial And More
April 03, 2023
Colorado and Leiden-based biotech company Mydecine Innovations Group (OTC: MYCOF) has shared its financial results and business highlights for the period ended December 31, 2022. In ciphers:
Via
Benzinga
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
January 03, 2023
What a year for psychedelics!
Via
Benzinga
Psyched: First Ayahuasca Pill Created, Psychedelics Legalization Predicted, UK's Research Support And More
December 19, 2022
Ayahuasca Pill Is Officially Here, Filament CEO Discusses Future Plans The first medical-grade drug candidate of the psychedelic ayahuasca is being developed.
Via
Benzinga
Psychedelic Company Sale: Mydecine Gets Over $2.5M For Wholly-Owned Tech Subsidiary Business
December 13, 2022
Mydecine Innovations Group Inc.
Via
Benzinga
Psyched: Musk's Empathy Tweets, Psychedelics In Congress, Oregon's Opt-Outs, MAPS' MDMA Trial And More
November 21, 2022
Elon Musk Joins Twitter Conversation Around Psychedelics: A Debate On Empathy
Via
Benzinga
Mydecine's Q3 Financials & Update, Sustained Target On Smoking Cessation For Next 12 Months
November 15, 2022
Mydecine Innovations Group (OTC: MYCOF), the psychedelics biotech company headquartered in Denver, Colorado with international offices in the Netherlands, reported its financial results and business...
Via
Benzinga
Psychedelics Biotechs Clearmind And Mydecine Share Consolidation And Subscription Agreements
September 26, 2022
In connection with recent stock splits, psychedelics biotech Clearmind Medicine Inc.
Via
Benzinga
World Class Leaders In Psychedelics Form Benzinga's Psychedelic Advisory Council—Get To Know Them
August 30, 2022
The Benzinga Psychedelics Advisory Council was introduced in March of 2022 with the sustained goal of better informing investors and general audience about the psychedelics financial and business...
Via
Benzinga
Mydecine Innovations Group Reports Q2 Financial Results And Management Updates
August 16, 2022
After the resignation of several key board members on August 12, Mydecine Innovations Group (OTC: MYCOF) reported its financial results. For the period corresponding to the six months ended June 30,...
Via
Benzinga
Two Psychedelic Companies File Patent Applications For Psilocybin And MDMA Analogues, Here's What Could Change
July 19, 2022
Mydecine (OTC: MYCOF) and Lobe Sciences (OTCQB: LOBEF), two companies in the psychedelics space, have filed patent applications.
Via
Benzinga
Government-Funded Smoking Cessation Trial Uses Mydecine's New Psilocybin-Derived MYCO-001, Recently FDA-Approved
June 17, 2022
Biotech company Mydecine Innovations Group (OTC: MYCOF) received FDA approval for their novel proprietary MYCO-001. This is the first clearance of the company’s drug product.
Via
Benzinga
Mydecine Announces 1-for-50 Reverse Stock Split
April 14, 2022
The board of directors of Mydecine Innovations Group Inc. (OTCPK:MYCOF) voted in favor of completing a reverse stock split. With this action, the company will consolidate all issued and outstanding...
Via
Benzinga
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
April 06, 2022
It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector.
Via
Benzinga
Benzinga's Unprecedented Psychedelics Investing Conference Lands In Miami On April 19th
February 09, 2022
The first Benzinga Psychedelics Capital Conference, the premier gathering of psychedelics industry leaders and forward-thinking investors, is coming to the Fontainebleau Miami Beach on April 19, 2022,...
Via
Benzinga
Year-End Summary: Marijuana & Psychedelic Compounds-Based Drug Stocks Index Went DOWN -33.6% In 2021!
January 02, 2022
Which index performed the best in 2021, the Marijuana Drug Stocks Index, or the Psychedelic Compounds-Based Drug Stocks Index? Which constituents contributed to their performances? This article has the...
Via
Talk Markets
Steep Decline In Cannabis & Psychedelic Compounds-Based Drug Stocks Continues: DOWN -16.6% MTD
December 24, 2021
All 12 constituents in the Marijuana & Psychedelic Compounds-Based Drug Stocks Index continue to decline. How do their performances compare month-to-date and YTD?
Via
Talk Markets
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.